These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 33941080)

  • 1. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
    J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
    Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
    J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
    Barbanti P; Egeo G; Aurilia C; d'Onofrio F; Albanese M; Cetta I; Di Fiore P; Zucco M; Filippi M; Bono F; Altamura C; Proietti S; Bonassi S; Vernieri F;
    J Headache Pain; 2022 Apr; 23(1):46. PubMed ID: 35397503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.
    Altamura C; Brunelli N; Marcosano M; Aurilia C; Egeo G; Lovati C; Favoni V; Perrotta A; Maestrini I; Schiano Di Cola F; d'Onofrio F; Finocchi C; Bertuzzo D; Bono F; Ranieri A; Albanese M; Messina R; Doretti A; Di Piero V; Cevoli S; Barbanti P; Vernieri F;
    J Neurol; 2022 Nov; 269(11):5848-5857. PubMed ID: 35763113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.
    Vernieri F; Brunelli N; Marcosano M; Aurilia C; Egeo G; Lovati C; Favoni V; Perrotta A; Maestrini I; Rao R; d'Onofrio L; Finocchi C; Aguggia M; Bono F; Ranieri A; Albanese M; Di Piero V; Cevoli S; Altamura C; Barbanti P;
    Eur J Neurol; 2023 Jan; 30(1):224-234. PubMed ID: 36097739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
    Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Lovati C; Bertuzzo D; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Schiano Di Cola F; Ranieri A; Colombo B; Bono F; Albanese M; Cevoli S; Barbanti P;
    Eur J Neurol; 2022 Apr; 29(4):1198-1208. PubMed ID: 34826192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
    Barbanti P; Egeo G; Proietti S; d'Onofrio F; Aurilia C; Finocchi C; Di Clemente L; Zucco M; Doretti A; Messina S; Autunno M; Ranieri A; Carnevale A; Colombo B; Filippi M; Tasillo M; Rinalduzzi S; Querzani P; Sette G; Forino L; Zoroddu F; Robotti M; Valenza A; Camarda C; Borrello L; Aguggia M; Viticchi G; Tomino C; Fiorentini G; Orlando B; Bonassi S; Torelli P;
    Neurol Ther; 2024 Jun; 13(3):611-624. PubMed ID: 38451463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry.
    Obach V; Velasco F; Alvarez Escudero R; Martín Bujanda M; Aranceta S; Fabregat N; Marco T; Ruisanchez A; Roncero N; Mínguez-Olaondo A; Ruibal M; Guisado-Alonso D; Moreira A; Cuadrado-Godia E; Echeverria A; Kortazar Zubizarreta I; López-Bravo A; Riesco N; González-Fernández L; Pola N; Manera P; Guerrero-Peral ÁL; Oterino Duran A; González-Osorio Y; Armand R; Fernández-Fernández S; García-Azorín D; García-Moncó JC
    J Headache Pain; 2023 Nov; 24(1):157. PubMed ID: 37993795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
    Ailani J; Andrews JS; Rettiganti M; Nicholson RA
    J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
    Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
    Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.